1 / 14

Advances in Sequential Therapy for Renal Cell Carcinoma: Maximizing Patient Benefit

This article reviews the potential of sequential therapy in renal cell carcinoma (RCC), highlighting the unique biological profiles of targeted agents and their clinical efficacy. By using a variety of antiangiogenic agents sequentially, patients can benefit from subsequent therapies without overlapping toxicities, ultimately improving both the quality and duration of life. The review discusses ongoing trials, potential biomarkers, and the rationale for sequential therapy, emphasizing that current evidence suggests negligible cross-resistance between tyrosine kinase inhibitors (TKIs) and effective treatment outcomes.

creola
Télécharger la présentation

Advances in Sequential Therapy for Renal Cell Carcinoma: Maximizing Patient Benefit

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sequential Therapy in Renal Cell Carcinoma J C Nunes Marques Serviço de Oncologia Médica Centro Hospitalar de Lisboa Ocidental

  2. Molecular Pathways and Targeted Therapies in Renal-Cell Carcinoma. Brugarolas J. N Engl J Med 2007;356:185-187.

  3. Angiogenesis: a target for anticancer therapy Rini. Clin Cancer Res 2007, 13 Faivre et al. Nat Ver Drug Disc 2007, 6 Homsi and Dand. Cancer control 2007, 14 Andrae et al. Genes Dev 2008, 22 Kerbel. N Engl J Med 2008, 358 Sonpavde et al. Expert Opin Investig Drugs 2008, 17 Ma and Adjei. CA Cancer J Clin 2009, 59

  4. Chronology and uses of available molecular-targeted agents in metastatic renal cell carcinoma in the U.S. and Europe. Hutson T E The Oncologist 2011;16:14-22

  5. Ongoing Phase III Trial: Pazopanib vs Sunitinib in the first-line treatment of patients with mRCC (COMPARZ) US National Institutes of Health Web Site http://www.clinicaltrials.gov/ct2/show/NCT00720941 acessed26oct2011

  6. Potencial Biomarkers in mRCC

  7. Escudier B, et al. Cancer 2009; 115 (10 Suppl): 2321-2326 1 Escudier et al. NEngJMed 2007; 356 2 Motzer et al. NEngJMed 2007; 356 4 Escudier et al. Lancet 2007; 370 10 Rixe et al. Lancet Oncol 2007; 8 12 Scharzberg et al. J Clin Oncol 2008; 26 13 Rini BI et al. J Clin Oncol 2008; 26 14 Rini BI et al. J Clin Oncol 2007; 25 15Sablin MP et al. J Clin Oncol 2007; 25

  8. Rational of sequential therapy • each targeted agent possesses a unique biologic profile • patients have benefited from subsequent therapy with a different antiangiogenic agent • full dose of each drug can be delivered without overlapping toxicities • additional PFS benefit can been achieved • the aim of therapy is to maximize the overall benefit to patient in terms of both quality and duration of life Sablin MP, et al. J Clin Oncol. 2007;25 (18S): Abstract 5038 Dham A, et al. J Clin Oncol. 2007;25(18S):Abstract 5106 Drabkin HÁ, et al. J Clin Oncol.2007;25(18S):Abstract 5041

  9. *available at http://clinicaltrials.gov

  10. Summary • Thesequentialapproachwithtargetedagentshaverevealedclinicalefficacy • Data suggeststhatthereisonlynegligibilecross-resistancebetweenTKIs • Inclinicalstudiesofsequentialtherapy, everolimuswaseffectiveaftertreatmentwithoneortwoTKIs • Inclinicalstudiesofsequentialtherapy, sequentialtreatmentwastolerableandtoxicitywaspredictable

More Related